TALS vs. EXAI, CALT, ITOS, KYTX, CABA, VALN, TSHA, HLVX, ALEC, and ADPT
Should you be buying Talaris Therapeutics stock or one of its competitors? The main competitors of Talaris Therapeutics include Exscientia (EXAI), Calliditas Therapeutics AB (publ) (CALT), iTeos Therapeutics (ITOS), Kyverna Therapeutics (KYTX), Cabaletta Bio (CABA), Valneva (VALN), Taysha Gene Therapies (TSHA), HilleVax (HLVX), Alector (ALEC), and Adaptive Biotechnologies (ADPT). These companies are all part of the "medical" sector.
Exscientia (NASDAQ:EXAI) and Talaris Therapeutics (NASDAQ:TALS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, community ranking, valuation, risk, dividends, media sentiment and earnings.
In the previous week, Exscientia had 14 more articles in the media than Talaris Therapeutics. MarketBeat recorded 14 mentions for Exscientia and 0 mentions for Talaris Therapeutics. Talaris Therapeutics' average media sentiment score of 0.38 beat Exscientia's score of 0.00 indicating that Exscientia is being referred to more favorably in the media.
Exscientia currently has a consensus target price of $9.75, indicating a potential upside of 104.83%. Given Talaris Therapeutics' higher probable upside, analysts plainly believe Exscientia is more favorable than Talaris Therapeutics.
Talaris Therapeutics has lower revenue, but higher earnings than Exscientia. Talaris Therapeutics is trading at a lower price-to-earnings ratio than Exscientia, indicating that it is currently the more affordable of the two stocks.
Talaris Therapeutics has a net margin of 0.00% compared to Talaris Therapeutics' net margin of -666.80%. Talaris Therapeutics' return on equity of -34.59% beat Exscientia's return on equity.
41.6% of Exscientia shares are held by institutional investors. Comparatively, 67.6% of Talaris Therapeutics shares are held by institutional investors. 16.5% of Talaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Talaris Therapeutics received 4 more outperform votes than Exscientia when rated by MarketBeat users. Likewise, 48.15% of users gave Talaris Therapeutics an outperform vote while only 36.00% of users gave Exscientia an outperform vote.
Exscientia has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Talaris Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500.
Summary
Exscientia beats Talaris Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Talaris Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TALS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TALS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Talaris Therapeutics Competitors List
Related Companies and Tools
